0707 GMT - Raffles Medical's recent share-price weakness may be short-lived, RHB Research says. Shares of the company slipped 11% from their mid-October high amid concerns that the reduction in the number of tests that travelers need to undergo, as part of vaccinated travel lane requirements, may hurt testing-related earnings. Travelers now only need to be tested upon completing their quarantine rather than also on arrival. However, RHB believes the rise in patient loads at healthcare facilities in 2022 should boost earnings and long-term growth. It keeps a buy rating and S$1.65 target price. Shares are 2.9% lower at S$1.33. (yongchang.chin@wsj.com)